

Mehlika Hazar-Rethinam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4128861/publications.pdf>

Version: 2024-02-01

10
papers

1,476
citations

1163117

8
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

3810
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 123-132.	3.0	30
2	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. <i>Nature Medicine</i> , 2019, 25, 1415-1421.	30.7	359
3	Using circulating tumor DNA (ctDNA) to predict surgical outcome and postoperative recurrence following neoadjuvant chemoradiation (CRT) for borderline resectable/locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 562-562.	1.6	2
4	Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in <i>BRAF</i> V600E Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 417-427.	9.4	61
5	A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. <i>Oncolmmunology</i> , 2018, 7, e1423172.	4.6	25
6	Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15.	3.0	17
7	Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	30
8	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. <i>Cancer Discovery</i> , 2018, 8, 1096-1111.	9.4	256
9	Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 272-272.	1.6	7
10	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. <i>Nature Communications</i> , 2017, 8, 1136.	12.8	686